Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 5,572 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Degenerative Conditions, Neurologic Clear all

Conditions: Alzheimer's Disease
Interventions: MSDC-0160, Placebo; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Entrapment Neuropathy
Interventions: Cryo-Touch III Device; Device
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Redwood City, California • Overland Park, Kansas

Conditions: Hyperglycemia Drug Induced
Interventions: REMD-477; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Dystonia
Interventions: Clinically optimized deep brain stimulation; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Friedreich Ataxia
Interventions: Vatiquinone, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 7 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more

Conditions: Loss of Consciousness, Parkinson Disease, Essential Tremor, Anesthesia
Interventions: Propofol; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer's Disease
Interventions: MK-1167, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Hallandale, Florida • Decatur, Georgia • Savannah, Georgia

Conditions: Parkinson's Disease and Parkinsonism, Glymphatic System
Interventions: Exercise--Rock Steady Boxing class; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 55 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lumbar Spine Degeneration
Interventions: INFUSE Bone Graft, Iliac Crest Bone Graft; Device · Other
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 5
States / cities: Mesa, Arizona • Los Angeles, California • Gulf Breeze, Florida + 2 more

Conditions: Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions: Placebo, Droxidopa; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more

Conditions: Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions: Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube; Drug · Device
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 30 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 16
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more

Conditions: Parkinson's Disease
Interventions: Glycerol Phenylbutyrate; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Parkinson's Disease
Interventions: Ropinirole Hydrochloride; Drug
Lead sponsor: Agarwal, Pinky, M.D.; Individual
Eligibility: 25 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Neovascular Age-related Macular Degeneration
Interventions: brolucizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more

Conditions: Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions: In-Home Technology System, Limited In-Home Technology; Device
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Wolfram Syndrome
Interventions: AMX0035; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dementia, Caregivers, Neurodegenerative Diseases, Brain Diseases
Interventions: Education and Skill-Building Rehabilitation (ESBR), Supplemental Education Materials; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Dasatinib, Quercetin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 55 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alzheimer's Disease
Interventions: AGN-242071, Placebo, Donepezil, Memantine; Drug
Lead sponsor: Allergan; Industry
Eligibility: 55 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 6
States / cities: Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more

Conditions: Juvenile Huntington Disease, Juvenile-Onset Huntington Disease
Interventions: Not listed
Lead sponsor: University of Iowa; Other
Eligibility: 4 Years to 30 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Sacramento, California • Iowa City, Iowa • Philadelphia, Pennsylvania + 2 more

Conditions: AL Amyloidosis
Interventions: Ixazomib, Cyclophosphamide, Dexamethasone; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: New York, New York

Conditions: Tourette Syndrome
Interventions: NeuroPace RNS® System Deep Brain Stimulator; Device
Lead sponsor: University of Florida; Other
Eligibility: 25 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia, Frontotemporal Dementia, Mixed Dementia
Interventions: Kinto Care Coaching; Behavioral
Lead sponsor: Kinto; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

Sleep-specific DBS Therapy in Parkinson's Disease

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Brain Networks and Consciousness

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson's Disease

INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables

AMX0035 in Adult Patients With Wolfram Syndrome

VA Cultivating Access to Resources, Education, and Skills for Dementia Caregivers

ALSENLITE: Senolytics for Alzheimer's Disease

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Brain Stimulation for the Treatment of Tourette Syndrome

Cerebrospinal Fluid Repository

Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers